Guardant Health is a biotechnology company that specializes in developing advanced genomic tests for cancer patients. The company focuses on providing innovative liquid biopsy solutions, which involve analyzing circulating tumor DNA from blood samples to help detect and monitor cancers more effectively. Their tests are designed to aid physicians in making informed treatment decisions, enabling personalized medicine approaches that can improve patient outcomes. Through their cutting-edge technology and extensive research, Guardant Health aims to transform cancer care by delivering actionable insights and facilitating early detection and ongoing management of the disease. Read More
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology, show that detecting ctDNA with the Guardant Reveal® blood test better predicts recurrence and overall survival than standard staging.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.
Medical technology, infection control systems, oncology radiotherapy solutions, and diagnostics innovation remain key healthcare growth themes heading into 2026—and CS Diagnostics Corp. (OTCQB: CSDX) is positioning itself at the intersection of both.
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that blew past Wall Street expectations. The report highlighted a dramatic acceleration in the adoption of its clonoSEQ diagnostic test, positioning the company as a
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025 financial results that comfortably beat both internal guidance and Wall Street estimates. The Colorado-based lung diagnostics specialist reported a
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military’s health insurance coverage, with no copay for average-risk individuals ages 45 and older.
As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor of 2025 toward a more fundamental, "constructive but selective" investment landscape. The firm’s analysts have identified
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp wave of year-end tax-loss harvesting has sent many mid-cap and commercial-stage biotech firms into a tailspin. Investors, eager
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Cardinal Health (NYSE:CAH) and its peers.
Looking back on healthcare providers & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including The Ensign Group (NASDAQ:ENSG) and its peers.
Guardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025.
Shares of diagnostics company Guardant Health (NASDAQ:GH)
jumped 1.8% in the afternoon session after Morgan Stanley raised its price target on the stock, reflecting heightened optimism about the company's potential. The firm's analyst, Shannon O’Callaghan, maintained an "Overweight" rating on Guardant Health while increasing the price target to $130.00 from $105.00. This action followed other positive price target adjustments from analysts in the recent past. Specifically, both BTIG and Canaccord Genuity also previously increased their price targets for the company. These collective revisions signaled a growing positive view of the stock among financial analysts.
